- Home
- NAKA vs CHRS Comparison
NAKA vs CHRS Comparison
Compare NAKA & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NAKA | CHRS |
|---|---|---|
| Founded | 2019 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 196.8M | 209.8M |
| IPO Year | 2023 | 2014 |
Fundamental Metrics
Financial Performance| Metric | NAKA | CHRS |
|---|---|---|
| Price | $5.08 | $1.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $0.75 | ★ $5.51 |
| AVG Volume (30 Days) | 184.2K | ★ 703.6K |
| Earning Date | 05-20-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 61.19 | ★ 472.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,514.38 | $73.08 |
| Revenue Next Year | $48.27 | $30.94 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.15 | $0.92 |
| 52 Week High | $15.60 | $2.62 |
Technical Indicators
Market Signals| Indicator | NAKA | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 59.88 | 32.18 |
| Support Level | $4.12 | $1.15 |
| Resistance Level | $5.11 | $1.44 |
| Average True Range (ATR) | 0.38 | 0.09 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 78.87 | 17.61 |
Price Performance
Historical ComparisonAbout NAKA Kindly MD Inc.
Nakamoto Inc is a Bitcoin company building a world-wide portfolio of Bitcoin-native companies to provide commercial and financial infrastructure for the next generation of capital markets.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.